Patented technology easily transforms distillate into a “free-flowing” powder matrix
Philadelphia, September 20, 2022 /PR Newswire/ — Zelira Therapeutics (ASX:ZLD, OTCQB:ZLDAF)Inc., a global leader in the research, development and commercialization of clinically validated cannabinoid pharmaceuticals, is pleased to announce the launch of ZYRAYDI™, a patented and licensable technology for the future of the medical cannabis industry. I am pleased to
ZYRAYDI™ is a proprietary Enhanced Distillate Capture and Dissolution Matrix (EDDDM) technology that virtually captures the distillate into a free-flowing powder matrix, increasing dissolution rates. With ZYRAYDI™, Zelira Therapeutics continues to create new and innovative methods for manufacturing pharmaceutical grade cannabinoid oral dosage forms such as capsules and tablets.
“ZYRAYDI™ solves two key problems that have hindered the wide acceptance of cannabinoid medicines: the difficulty of formulating solid oral medications using distillates and the ability to convert capsules and tablets into It has a slow rate of dissolution in the body,” says Dr. Oldale Odumos, CEO of Zelira Therapeutics. “We strongly believe that the availability of the ability to consistently formulate, validate and commercialize dosage forms that closely resemble current medicines will significantly expand the market for cannabinoid-based medicines.”
Designed to be a valuable tool for cannabinoid producers worldwide, ZYRAYDI™ requires minimal capital expenditure on equipment and raw materials and is readily adaptable to existing capsule and tablet programs. ZYRAYDI Matrix contains pharmaceutical-grade excipients that are on the FDA-approved GRAS (Generally Recognized As Safe) ingredient list and are tailored to meet requirements such as vegan, gluten-free, allergen-free and non-GMO You can.
Zelira Therapeutics (ASX:ZLD, OTCQB:ZLDAF) is a leading global therapeutic cannabinoid company with access to the world’s largest and fastest growing cannabinoid pharmaceutical market. Zelira has a unique portfolio of revenue-generating products and a pipeline of candidates in clinical development that are positioned to enter the global market.
The Company is focused on developing cannabinoid-based branded medicines for the treatment of various medical conditions in its Rx business, including insomnia, autism and chronic non-cancer pain.
We have two proprietary formulations under the HOPE™ brand, Australia, pennsylvania is licensed in Louisiana When washington dc, and other states in the United States are expected to follow. Zelira also makes money from: Australia From the proprietary and patented Zenivol™, the leading cannabinoid-based medicine for the treatment of chronic insomnia. Zenivol™ Successfully Completes World First Phase 1b A clinical trial of chronic insomnia found to be a safe and effective treatment.
In 2020, Zerira partnered with SprinJene® Natural to develop and commercialize natural and organic oral care products under the Sprinjene CBD brand as part of Zerira’s OTC business. The Sprinjene CBD toothpaste product is the first in a line of scientifically formulated hemp-derived oral care products that contain cannabinoids and are based on patented technology of black seed oil and zinc.
We work with world-leading researchers and organizations, including: Curtin University of Perth, Western Australiaof the Telethon Kids Institute Perth; university Western Australiaof Perth; St. Vincent’s Hospital melbourne, australiaand Children’s Hospital Philadelphia in (CHOP) usa.
Media Contacts (Zelira Therapeutics):
GVM communication
Brenda Lowry
[email protected]
Source: Zelira Therapeutics